-
Something wrong with this record ?
The Role of Multidimensional Prognostic Index to Identify Hospitalized Older Adults with COVID-19 Who Can Benefit from Remdesivir Treatment: An Observational, Prospective, Multicenter Study
C. Custodero, N. Veronese, E. Topinkova, H. Michalkova, MC. Polidori, A. Cella, AJ. Cruz-Jentoft, CAF. von Arnim, M. Azzini, H. Gruner, A. Castagna, G. Cenderello, R. Custureri, T. Zieschang, A. Padovani, E. Sanchez-Garcia, A. Pilotto, Study...
Language English Country New Zealand
Document type Observational Study, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2008-06-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest)
from 2008-06-01 to 1 year ago
Psychology Database (ProQuest)
from 2008-06-01 to 1 year ago
- MeSH
- COVID-19 * MeSH
- COVID-19 Drug Treatment MeSH
- Geriatric Assessment methods MeSH
- Frailty * drug therapy MeSH
- Humans MeSH
- Prognosis MeSH
- Prospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Data regarding the importance of multidimensional frailty to guide clinical decision making for remdesivir use in older patients with coronavirus disease 2019 (COVID-19) are largely unexplored. OBJECTIVE: The aim of this research was to evaluate if the Multidimensional Prognostic Index (MPI), a multidimensional frailty tool based on the Comprehensive Geriatric Assessment (CGA), may help physicians in identifying older hospitalized patients affected by COVID-19 who might benefit from the use of remdesivir. METHODS: This was a multicenter, prospective study of older adults hospitalized for COVID-19 in 10 European hospitals, followed-up for 90 days after hospital discharge. A standardized CGA was performed at hospital admission and the MPI was calculated, with a final score ranging between 0 (lowest mortality risk) and 1 (highest mortality risk). We assessed survival with Cox regression, and the impact of remdesivir on mortality (overall and in hospital) with propensity score analysis, stratified by MPI = 0.50. RESULTS: Among 496 older adults hospitalized for COVID-19 (mean age 80 years, female 59.9%), 140 (28.2% of patients) were treated with remdesivir. During the 90 days of follow-up, 175 deaths were reported, 115 in hospital. Remdesivir treatment significantly reduced the risk of overall mortality (hazard ratio [HR] 0.54, 95% confidence interval CI 0.35-0.83 in the propensity score analysis) in the sample as whole. Stratifying the population, based on MPI score, the effect was observed only in less frail participants (HR 0.47, 95% CI 0.22-0.96 in propensity score analysis), but not in frailer subjects. In-hospital mortality was not influenced by remdesivir use. CONCLUSIONS: MPI could help to identify less frail older adults hospitalized for COVID-19 who could benefit more from remdesivir treatment in terms of long-term survival.
Department of Geriatric Care Orthogeriatrics and Rehabilitation Galliera Hospital Genoa Italy
Department of Geriatrics 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Interdisciplinary Medicine University of Bari Aldo Moro Bari Italy
Division of Geriatrics University Medical Center Goettingen Goettingen Germany
Faculty of Health and Social Sciences University of South Bohemia Ceske Budejovice Czech Republic
Geriatrics Unit Mater Salutis Hospital Legnago ULSS 9 Scaligera Verona Italy
Geriatrics Unit Pugliese Ciaccio Hospital Catanzaro Italy
Infectious Disease Unit Sanremo Hospital ASL 1 Imperiese Sanremo Italy
Klinikum Oldenburg AöR Oldenburg University Oldenburg Germany
Neurology Unit Department of Clinical and Experimental Sciences University of Brescia Brescia Italy
Servicio de Geriatría Hospital Universitario Ramón y Cajal Madrid Spain
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010870
- 003
- CZ-PrNML
- 005
- 20230801132650.0
- 007
- ta
- 008
- 230718s2023 nz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s40266-023-01036-2 $2 doi
- 035 __
- $a (PubMed)37310575
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a nz
- 100 1_
- $a Custodero, Carlo $u Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy
- 245 14
- $a The Role of Multidimensional Prognostic Index to Identify Hospitalized Older Adults with COVID-19 Who Can Benefit from Remdesivir Treatment: An Observational, Prospective, Multicenter Study / $c C. Custodero, N. Veronese, E. Topinkova, H. Michalkova, MC. Polidori, A. Cella, AJ. Cruz-Jentoft, CAF. von Arnim, M. Azzini, H. Gruner, A. Castagna, G. Cenderello, R. Custureri, T. Zieschang, A. Padovani, E. Sanchez-Garcia, A. Pilotto, Study Group Investigators
- 520 9_
- $a BACKGROUND: Data regarding the importance of multidimensional frailty to guide clinical decision making for remdesivir use in older patients with coronavirus disease 2019 (COVID-19) are largely unexplored. OBJECTIVE: The aim of this research was to evaluate if the Multidimensional Prognostic Index (MPI), a multidimensional frailty tool based on the Comprehensive Geriatric Assessment (CGA), may help physicians in identifying older hospitalized patients affected by COVID-19 who might benefit from the use of remdesivir. METHODS: This was a multicenter, prospective study of older adults hospitalized for COVID-19 in 10 European hospitals, followed-up for 90 days after hospital discharge. A standardized CGA was performed at hospital admission and the MPI was calculated, with a final score ranging between 0 (lowest mortality risk) and 1 (highest mortality risk). We assessed survival with Cox regression, and the impact of remdesivir on mortality (overall and in hospital) with propensity score analysis, stratified by MPI = 0.50. RESULTS: Among 496 older adults hospitalized for COVID-19 (mean age 80 years, female 59.9%), 140 (28.2% of patients) were treated with remdesivir. During the 90 days of follow-up, 175 deaths were reported, 115 in hospital. Remdesivir treatment significantly reduced the risk of overall mortality (hazard ratio [HR] 0.54, 95% confidence interval CI 0.35-0.83 in the propensity score analysis) in the sample as whole. Stratifying the population, based on MPI score, the effect was observed only in less frail participants (HR 0.47, 95% CI 0.22-0.96 in propensity score analysis), but not in frailer subjects. In-hospital mortality was not influenced by remdesivir use. CONCLUSIONS: MPI could help to identify less frail older adults hospitalized for COVID-19 who could benefit more from remdesivir treatment in terms of long-term survival.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a křehkost $x farmakoterapie $7 D000073496
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a farmakoterapie COVID-19 $7 D000093485
- 650 _2
- $a geriatrické hodnocení $x metody $7 D015577
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Veronese, Nicola $u Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, via del Vespro, 141, 90127, Palermo, Italy. nicola.veronese@unipa.it $1 https://orcid.org/000000029328289X
- 700 1_
- $a Topinkova, Eva $u Department of Geriatrics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Faculty of Health and Social Sciences, University of South Bohemia, Ceske Budejovice, Czech Republic
- 700 1_
- $a Michalkova, Helena $u Department of Geriatrics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Faculty of Health and Social Sciences, University of South Bohemia, Ceske Budejovice, Czech Republic
- 700 1_
- $a Polidori, Maria Cristina $u Ageing Clinical Research, Department II of Internal Medicine and Center for Molecular Medicine, University of Cologne, Cologne, Germany
- 700 1_
- $a Cella, Alberto $u Department of Geriatric Care, Orthogeriatrics and Rehabilitation, Galliera Hospital, Genoa, Italy
- 700 1_
- $a Cruz-Jentoft, Alfonso J $u Servicio de Geriatría, Hospital Universitario Ramón y Cajal, (IRYCIS), Madrid, Spain
- 700 1_
- $a von Arnim, Christine A F $u Division of Geriatrics, University Medical Center Goettingen, Goettingen, Germany
- 700 1_
- $a Azzini, Margherita $u Geriatrics Unit, "Mater Salutis" Hospital, Legnago ULSS 9 Scaligera, Verona, Italy
- 700 1_
- $a Gruner, Heidi $u Serviço de Medicina Interna, Hospital Curry Cabral, Centro Hospitalar Universitário Lisboa Central/Universidade Nova de Lisboa, Lisbon, Portugal
- 700 1_
- $a Castagna, Alberto $u Geriatrics Unit, "Pugliese Ciaccio" Hospital, Catanzaro, Italy
- 700 1_
- $a Cenderello, Giovanni $u Infectious Disease Unit, Sanremo Hospital, ASL 1 Imperiese, Sanremo, Italy
- 700 1_
- $a Custureri, Romina $u Department of Geriatric Care, Orthogeriatrics and Rehabilitation, Galliera Hospital, Genoa, Italy
- 700 1_
- $a Zieschang, Tania $u Klinikum Oldenburg AöR, Oldenburg University, Oldenburg, Germany
- 700 1_
- $a Padovani, Alessandro $u Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
- 700 1_
- $a Sanchez-Garcia, Elisabet $u Servicio de Geriatría, Hospital Universitario Ramón y Cajal, (IRYCIS), Madrid, Spain
- 700 1_
- $a Pilotto, Alberto $u Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy $u Department of Geriatric Care, Orthogeriatrics and Rehabilitation, Galliera Hospital, Genoa, Italy
- 710 2_
- $a Study Group Investigators
- 773 0_
- $w MED00001454 $t Drugs & aging $x 1179-1969 $g Roč. 40, č. 7 (2023), s. 643-651
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37310575 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132646 $b ABA008
- 999 __
- $a ok $b bmc $g 1963341 $s 1197135
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 40 $c 7 $d 643-651 $e 20230613 $i 1179-1969 $m Drugs &aging $n Drugs Aging $x MED00001454
- LZP __
- $a Pubmed-20230718